Key Takeaways
- Sage is laying off around 165 employees, including some corporate leaders, to preserve cash following a series of R&D setbacks.
- It is the second round of layoffs for Sage after the company cut 40% of its workforce last year after missing the approval of Zurzuvae in major depressive disorder.
- Chief financial officer Kimi Iguchi and chief technology and innovation officer Matt Lasmanis are among the management that will depart.
Sage Therapeutics is laying off 33% of its workforce, including 55% of the company’s R&D organization and some of its corporate leadership staff, as it seeks to preserve cash following R&D setbacks
It’s the second round of significant layoffs for Sage in two years. Last year, the
